Integrated Safety Analysis of Vedolizumab for the Treatment of Ulcerative Colitis or Crohn's Disease

被引：0
|
作者：
Colombel, Jean-Frederic
Sands, Bruce E.
Feagan, Brian G.
Loftus, Edward V.
Sankoh, Serap
Fox, Irving
Parikh, Asit
Milch, Catherine
机构：
来源：
GASTROENTEROLOGY | 2013年 / 144卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：S113 / S113
页数：1
相关论文
共 50 条
  • [1] Safety of vedolizumab in the treatment of Crohn's disease and ulcerative colitis
    Hagan, Matilda
    Cross, Raymond K.
    EXPERT OPINION ON DRUG SAFETY, 2015, 14 (09) : 1473 - 1479
  • [2] The safety of vedolizumab for ulcerative colitis and Crohn's disease
    Colombel, Jean-Frederic
    Sands, Bruce E.
    Rutgeerts, Paul
    Sandborn, William
    Danese, Silvio
    D'Haens, Geert
    Panaccione, Remo
    Loftus, Edward V., Jr.
    Sankoh, Serap
    Fox, Irving
    Parikh, Asit
    Milch, Catherine
    Abhyankar, Brihad
    Feagan, Brian G.
    GUT, 2017, 66 (05) : 839 - 851
  • [3] Vedolizumab for the treatment of ulcerative colitis and Crohn's disease
    McLean, Leon P.
    Shea-Donohue, Terez
    Cross, Raymond K.
    IMMUNOTHERAPY, 2012, 4 (09) : 883 - 898
  • [4] Long-term Safety Analysis of Vedolizumab for Treatment of Crohn's Disease and Ulcerative Colitis
    Ritter, Timothy E.
    Fourment, Chris
    Van Anglen, Lucinda J.
    Hardin, Thomas C.
    Schroeder, Claudia P.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 : S399 - S399
  • [5] Long-term Safety of Vedolizumab for the Treatment of Ulcerative Colitis or Crohn's Disease
    Colombel, Jean-Frederic
    Sands, Bruce
    Hanauer, Stephen
    Rutgeerts, Paul
    Sandborn, William
    Danese, Silvio
    D'Haens, Geert
    Panaccione, Remo
    Sankoh, Serap
    Fox, Irving
    Parikh, Asit
    Milch, Catherine
    Feagan, Brian
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2013, 108 : S502 - S503
  • [6] Is there a role for vedolizumab in the treatment of ulcerative colitis and Crohn's disease?
    Gilroy, Leah
    Allen, Patrick B.
    CLINICAL AND EXPERIMENTAL GASTROENTEROLOGY, 2014, 7 : 163 - 172
  • [7] Vedolizumab Long-term Efficacy and Safety in the Treatment of ulcerative Colitis and Crohn's Disease in Adults
    不详
    VISCERAL MEDICINE, 2017, 33 (05) : 391 - 391
  • [8] Benefit–Risk Assessment of Vedolizumab in the Treatment of Crohn’s Disease and Ulcerative Colitis
    Robert Battat
    Christopher Ma
    Vipul Jairath
    Reena Khanna
    Brian G. Feagan
    Drug Safety, 2019, 42 : 617 - 632
  • [9] Efficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn's Disease Patients Stratified by Age
    Yajnik, Vijay
    Khan, Nabeel
    Dubinsky, Marla
    Axler, Jeffrey
    James, Alexandra
    Abhyankar, Brihad
    Lasch, Karen
    ADVANCES IN THERAPY, 2017, 34 (02) : 542 - 559
  • [10] A comparative efficacy and safety analysis of subcutaneous infliximab and vedolizumab in patients with Crohn's Disease and Ulcerative Colitis
    Peyrin-Biroulet, L.
    Arkkila, P.
    Armuzzi, A.
    Atreya, R.
    Danese, S.
    Ferrante, M.
    Guardiola, J.
    Jahnsen, J.
    Louis, E.
    Lukas, M.
    Reinisch, W.
    Roblin, X.
    Smith, P. J.
    Kwon, T. S.
    Kim, J. Y.
    Yoon, S. W.
    Kim, D. H.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I1116 - I117
12345